

Bezlotoxumab Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
1.19	28.09.2024	809029-00020	Date of first issue: 22.07.2016

SECTION 1. PRODUCT AND COMPANY IDENTIFICATION

Product name	:	Bezlotoxumab Formulation		
Manufacturer or supplier's o	leta	nils		
Company name of supplier	:	MSD		
Address	:	126 E. Lincoln Avenue		
		Rahway, New Jersey U.S.A. 07065		
Telephone	:	908-740-4000		
Emergency telephone	:	1-908-423-6000		
E-mail address	:	EHSDATASTEWARD@msd.com		
Recommended use of the chemical and restrictions on use				

Recommended use : Pharmaceutical Restrictions on use : Not applicable

SECTION 2. HAZARDS IDENTIFICATION

GHS Classification

Not a hazardous substance or mixture.

GHS label elements

No hazard pictogram, no signal word, no hazard statement(s), no precautionary statement(s) required.

Other hazards

None known.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

Chemical name	CAS-No.	Concentration (% w/w)
Bezlotoxumab	1246264-45-8	>= 1 -< 5

SECTION 4. FIRST AID MEASURES

If inhaled	:	If inhaled, remove to fresh air.
		Get medical attention if symptoms occur.
In case of skin contact	:	Wash with water and soap as a precaution.
		Get medical attention if symptoms occur.
In case of eye contact	:	Flush eyes with water as a precaution.
		Get medical attention if irritation develops and persists.
If swallowed	:	If swallowed, DO NOT induce vomiting.
		Get medical attention if symptoms occur.
		Rinse mouth thoroughly with water.
Most important symptoms	:	None known.
and effects, both acute and		
delayed		
Protection of first-aiders	:	No special precautions are necessary for first aid responders.
Notes to physician	:	Treat symptomatically and supportively.



Bezlotoxumab Formulation

/ersion I.19	Revision Date: 28.09.2024		9029-00020	Date of last issue: 30.09.2023 Date of first issue: 22.07.2016
SECTION	5. FIRE-FIGHTING ME	ASL	IRES	
Suital	ble extinguishing media	:	Water spray Alcohol-resistant Carbon dioxide ((Dry chemical	
Unsu media	itable extinguishing a	:	None known.	
Speci fightir	ific hazards during fire ng	:	Exposure to com	bustion products may be a hazard to health.
Haza ucts	rdous combustion prod-	:	Carbon oxides	
Speci ods	ific extinguishing meth-	:	cumstances and Use water spray	g measures that are appropriate to local cir- the surrounding environment. to cool unopened containers. ged containers from fire area if it is safe to d
	ial protective equipment e-fighters	:	necessary.	ned breathing apparatus for firefighting if tective equipment.

Personal precautions, protec- tive equipment and emer- gency procedures	Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).	
Environmental precautions	Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Prevent spreading over a wide area (e.g., by containment oil barriers). Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.	or
Methods and materials for containment and cleaning up	Soak up with inert absorbent material. For large spills, provide diking or other appropriate containment to keep material from spreading. If diked material can be pumped, store recovered material in appropriate container. Clean up remaining materials from spill with suitable absorbent. Local or national regulations may apply to releases and disposal of this material, as well as those materials and its employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regard	ems



Bezlotoxumab Formulation

Version 1.19	Revision Date: 28.09.2024	SDS Number: 809029-00020	Date of last issue: 30.09.2023 Date of first issue: 22.07.2016
		certain local	or national requirements.
SECTION	7. HANDLING AND S	TORAGE	
Tech	nical measures	•	ering measures under EXPOSURE S/PERSONAL PROTECTION section.
	/Total ventilation e on safe handling	: Handle in ad practice, ba assessment	prevent spills, waste and minimize release to the
Hygie	ene measures	flushing sys place. When using Wash conta The effectiv engineering appropriate industrial hy	to chemical is likely during typical use, provide eye tems and safety showers close to the working do not eat, drink or smoke. minated clothing before re-use. e operation of a facility should include review of controls, proper personal protective equipment, degowning and decontamination procedures, giene monitoring, medical surveillance and the histrative controls.
Conditions for safe storage : Keep in properly labeled containers. Store in accordance with the particular national reg			
Mater	rials to avoid		with the following product types:

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Ingredients with workplace control parameters

Components	CAS-No.	Value type (Form of	Control parame- ters / Permissible	Basis
		exposure)	concentration	
Bezlotoxumab	1246264-45-	TWA	5.0 mg/m3 (OEB	Internal
	8		1)	
	0		1)	

Engineering measures	:	Use appropriate engineering controls and manufacturing technologies to control airborne concentrations (e.g., drip- less quick connections). All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment. Laboratory operations do not require special containment.
Personal protective equipme	ent	
Respiratory protection	:	If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.
Filter type	:	Particulates type
Hand protection Material	:	Chemical-resistant gloves



Bezlotoxumab Formulation

/ersion 1.19	Revision Date: 28.09.2024		S Number: 9029-00020	Date of last issue: 30.09.2023 Date of first issue: 22.07.2016
	protection and body protection	:	If the work envir mists or aeroso Wear a faceship potential for dire aerosols.	isses with side shields or goggles. ronment or activity involves dusty conditions ls, wear the appropriate goggles. eld or other full face protection if there is a ect contact to the face with dusts, mists, or r laboratory coat.
	9. PHYSICAL AND CHE	= МП		•
		_ 1411		
	arance	•	Aqueous soluti	
Color		:	Colorless to pa	-
Odor		:	No data availa	
Odor	Threshold	:	No data availa	ble
рН		:	5.7 - 6.3	
Meltir	ng point/freezing point	:	No data availa	ble
Initial range	boiling point and boiling	:	No data availa	ble
Flash	point	:	No data availa	ble
Evap	oration rate	:	No data availa	ble
Flam	mability (solid, gas)	:	Not applicable	
Flam	mability (liquids)	:	No data availa	ble
	r explosion limit / Upper nability limit	:	No data availa	ble
	r explosion limit / Lower nability limit	:	No data availa	ble
Vapo	r pressure	:	No data availa	ble
Relat	ive vapor density	:	No data availa	ble
Relat	ive density	:	No data availa	ble
Dens	ity	:	1.0146 g/cm ³	
	ility(ies) ater solubility	:	No data availa	ble
	ion coefficient: n-	:	Not applicable	
	ol/water gnition temperature	:	No data availa	ble



Bezlotoxumab Formulation

Version 1.19	Revision Date: 28.09.2024		S Number: 9029-00020	Date of last issue: 30.09.2023 Date of first issue: 22.07.2016
Decomposition temperature		:	No data available	e
Viscosity Viscosity, dynamic		:	1.2 mPa.s (25 °	C)
Vi	scosity, kinematic	:	1.833 mm²/s (4	°C)
			1.183 mm²/s (25	5 °C)
Explo	osive properties	:	Not explosive	
Oxidi	zing properties	:	The substance of	r mixture is not classified as oxidizing.
Mole	cular weight	:	No data available	e
	cle characteristics cle size	:	Not applicable	

SECTION 10. STABILITY AND REACTIVITY

Reactivity	:	Not classified as a reactivity hazard.
Chemical stability	:	Stable under normal conditions.
Possibility of hazardous reac-	:	Can react with strong oxidizing agents.
tions		
Conditions to avoid	:	None known.
Incompatible materials	:	Oxidizing agents
Hazardous decomposition products	:	No hazardous decomposition products are known.

SECTION 11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure

Inhalation Skin contact Ingestion Eye contact

Acute toxicity

Not classified based on available information.

Components:

Bezlotoxumab:

Acute toxicity (other routes of
administration)LD50 (Mouse): > 125 mg/kg
Application Route: Intravenous
Remarks: No adverse effect has been observed in acute tox-
icity tests.

Skin corrosion/irritation

Not classified based on available information.

Serious eye damage/eye irritation

Not classified based on available information.



Bezlotoxumab Formulation

Version 1.19	Revision Date: 28.09.2024	SDS Number: 809029-00020	Date of last issue: 30.09.2023 Date of first issue: 22.07.2016
Resp	iratory or skin sensi	tization	
Skin	sensitization		
Not c	lassified based on ava	ailable information.	
-	iratory sensitization lassified based on ava		
	n cell mutagenicity lassified based on ava	ailable information.	
	inogenicity lassified based on ava	ailable information.	
-	oductive toxicity lassified based on ava	ailable information.	
	F-single exposure lassified based on ava	ailable information.	
	F-repeated exposure lassified based on ava		
Repe	ated dose toxicity		
Com	ponents:		
Bezlo	otoxumab:		
Spec		: Mouse	
NOA		: 50 mg/kg	
	cation Route sure time	: Intravenous : 15 d	
Rema			adverse effects were reported
Spec	ies	: Mouse	
NOAI	EL	: 125 mg/kg	
	cation Route	: Intravenous	
Expo Rema	sure time arks	: 21 d : No significant	adverse effects were reported
Aspii	ration toxicity		
Not c	lassified based on ava	ailable information.	
Expe	rience with human e	exposure	
Com	ponents:		
Bezlo	otoxumab:		
Inhala	ation	: Symptoms: Na	ausea, Headache, Diarrhea, Fever

SECTION 12. ECOLOGICAL INFORMATION

Ecotoxicity No data available



Bezlotoxumab Formulation

ersion .19	Revision Date: 28.09.2024	SDS Number: 809029-00020	Date of last issue: 30.09.2023 Date of first issue: 22.07.2016				
	stence and degradat	bility					
No da	No data available						
	Bioaccumulative potential No data available						
Mobility in soil No data available							
Other adverse effects No data available							
ECTION	13. DISPOSAL CONS	SIDERATIONS					
Dispo	osal methods						
Waste	Waste from residues :		Do not dispose of waste into sewer. Dispose of in accordance with local regulations.				
Conta	minated packaging	: Empty contain handling site for	 Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product. 				

UNRTDG

Not regulated as a dangerous good

IATA-DGR

Not regulated as a dangerous good

IMDG-Code

Not regulated as a dangerous good

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

Domestic regulation

NOM-002-SCT

Not regulated as a dangerous good

Special precautions for user

Not applicable

SECTION 15. REGULATORY INFORMATION

Safety, health and environmental regulations/legislation specific for the substance or mixture

Federal Law for the control of chemical precursors, : Not applicable essential chemical products and machinery for producing capsules, tablets and pills.

The ingredients of this product are reported in the following inventories: AICS : not determined



Bezlotoxumab Formulation

Version	Revision Date: 28.09.2024	SDS Number:	Date of last issue: 30.09.2023
1.19		809029-00020	Date of first issue: 22.07.2016
DSL		: not determined : not determined	

SECTION 16. OTHER INFORMATION

Revision Date	:	28.09.2024
Date format	:	dd.mm.yyyy

Full text of other abbreviations

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR -Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan): ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature: SDS - Safety Data Sheet: TCSI - Taiwan Chemical Substance Inventory: TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

Sources of key data used to : compile the Material Safety Data Sheet

Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, http://echa.europa.eu/

The information is considered as correct, but not exhaustive, and will be used only as a guide, which is based in the current knowledge of the substance or mixture, and is applicable to proper safety precautions for the product.





Bezlotoxumab Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
1.19	28.09.2024	809029-00020	Date of first issue: 22.07.2016

MX / Z8